Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00585507 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy and Safety of 500mg of Fulvestrant

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary and study completion dates: Mar 15, 2026 to Mar 15, 2027v20
  2. Primary and study completion dates: Mar 15, 2025 to Mar 15, 2026v19
  3. Primary and study completion dates: Jun 30, 2023 to Mar 15, 2025v18
  4. Primary and study completion dates: May 31, 2022 to Jun 30, 2023v17
  5. Primary and study completion dates: Apr 2021 to May 31, 2022v16
Show 14 earlier versionsHide 14 earlier versions
  1. Primary and study completion dates: Apr 2020 to Apr 2021v15
  2. Primary and study completion dates: Dec 2018 to Apr 2020v14
  3. Primary completion date: Sep 2017 to Dec 2018 Completion date: Dec 2017 to Dec 2018v13 Show 1 more changeShow less
    • Completion date: Dec 2017 to Dec 2018
  4. Primary completion date: Sep 2016 to Sep 2017 Completion date: Nov 2016 to Dec 2017v12 Show 1 more changeShow less
    • Completion date: Nov 2016 to Dec 2017
  5. Primary completion date: Jun 2015 to Sep 2016 Completion date: Sep 2015 to Nov 2016 · Study title shortened, about 16 wordsv11 Show 2 more changesShow less
    • Completion date: Sep 2015 to Nov 2016
    • Study title shortened, about 16 words

    See this version in full on ClinicalTrials.gov ↗

  6. Primary completion date: Jun 2014 to Jun 2015 Completion date: Jul 2014 to Sep 2015v10 Show 1 more changeShow less
    • Completion date: Jul 2014 to Sep 2015
  7. Primary completion date: Dec 2013 to Jun 2014 Completion date: Mar 2014 to Jul 2014v9 Show 1 more changeShow less
    • Completion date: Mar 2014 to Jul 2014
  8. Primary completion date: Sep 2013 to Dec 2013 Completion date: Sep 2013 to Mar 2014v8 Show 1 more changeShow less
    • Completion date: Sep 2013 to Mar 2014
  9. Primary completion date: Apr 2009 to Sep 2013 Completion date: Aug 2013 to Sep 2013v7 Show 1 more changeShow less
    • Completion date: Aug 2013 to Sep 2013
  10. Completion date: Sep 2011 to Aug 2013 Study arms: 0 to 1 · Eligibility criteria expanded, about 4 wordsv6 Show 2 more changesShow less
    • Study arms: 0 to 1
    • Eligibility criteria expanded, about 4 words

    See this version in full on ClinicalTrials.gov ↗

  11. Completion date: Sep 2011 Site details revised at 2 of 5 sitesv5 Show 1 more changeShow less
    • Site details revised at 2 of 5 sites
  12. Re-verified, no change to tracked fieldsv4
  13. Primary completion date: Apr 2008 to Apr 2009v3
  14. Trial status: Recruiting to Active, Not Recruiting Site details revised at 5 of 5 sitesv2 Show 1 more changeShow less
    • Site details revised at 5 of 5 sites
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Fulvestrant has proven effective in the treatment of hormone receptor positive metastatic breast cancer. The dose used in studies so far has been well tolerated and may be too low for optimal effectiveness. In this study, a higher dose will be used to see whether an improved outcome will result.
Trial Details
NCT Number NCT00585507
Lead Sponsor Beth Israel Deaconess Medical Center
Collaborators: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Lowell General Hospital, University of Colorado, Denver, University of Maryland Greenebaum Cancer Center, South Shore Hospital
Conditions Breast Cancer
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov